Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pembrolizumab + imiquimod + sargramostim + cryotherapy
- Development stage
- Unknown
- Lead developer
- Washington University School of Medicine
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Topical, Intralesional
01
Overview
This combination therapy is a multi-modal immunotherapy regimen being evaluated in a Phase IB pilot study (NCT03982004) by Washington University School of Medicine for patients with cutaneous metastatic breast cancer. The regimen integrates the PD-1 inhibitor pembrolizumab with local treatments designed to prime the immune system: epicutaneous cryotherapy (to induce tumor cell lysis and antigen release), topical imiquimod (a TLR7 agonist to activate innate immune cells), and intralesional GM-CSF (sargramostim, to recruit and differentiate dendritic cells). This "in situ" vaccination approach is intended to convert the local tumor site into a site of immune activation, potentially leading to systemic (abscopal) anti-tumor responses when combined with systemic checkpoint blockade.
- Brand names
- KeytrudaAldaraLeukine
- Other names
- Epicutaneous cryoimmunotherapyEC
02
Targets
CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)TLR7 (Toll-like receptor 7)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on pembrolizumab + imiquimod + sargramostim + cryotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pembrolizumab + imiquimod + sargramostim + cryotherapy.